Champions Oncology Granted Full Accreditation by the AAALAC

Aug 8, 2018 8:30:17 AM / by Paul McGarry

Hackensack, NJ – August 8, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that its new facility in Rockville, MD has been granted Full Accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.  AAALAC commended Champions for the quality and dedication of the staff, the superior quality of the animal facilities, the excellent program of veterinary medical care, and the highly knowledgeable and conscientious Institutional Animal Care and Use Committee.

The new facility was designed and constructed in the first half of 2017 with operations initiated in July 2017.  The purpose-built facility has state-of-the-art equipment, technology, and infrastructure, including individually ventilated caging, and automated water systems.

Dr. Ronnie Morris, CEO of Champions Oncology commented: “The rapidity with which our Program attained Full Accreditation by AAALAC highlights our dedication to animal welfare and providing the highest quality research data to our collaborators.  We are delighted and proud to join the elite group of AAALAC-accredited institutions.”

AAALAC International is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs.  Nearly 1,000 companies, universities, hospitals, government agencies and other research institutions in 46 countries have earned AAALAC accreditation, demonstrating their commitment to responsible animal care and use. These institutions volunteer to participate in AAALAC's program, in addition to complying with the local, state and federal laws that regulate animal research.

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company’s TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions’ Personalized Oncology Solutions business. For more information, please visit

Investor Contact:

Brett Maas
Hayden IR
(646) 536-7331

James Carbonara
Hayden IR